Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Interleukin enhancer-binding factor 3 (ILF3) (AA 1-270) antibody

ILF3 Reactivity: Human WB, IHC, IP, IF Host: Rabbit Polyclonal unconjugated
Catalog No. ABIN3023310
  • Target See all Interleukin enhancer-binding factor 3 (ILF3) Antibodies
    Interleukin enhancer-binding factor 3 (ILF3)
    Binding Specificity
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 1-270
    Reactivity
    • 56
    • 40
    • 37
    • 14
    • 11
    • 11
    • 10
    • 5
    • 5
    • 5
    • 2
    • 2
    • 1
    • 1
    Human
    Host
    • 52
    • 2
    • 1
    Rabbit
    Clonality
    • 45
    • 11
    Polyclonal
    Conjugate
    • 42
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    Un-conjugated
    Application
    • 36
    • 16
    • 11
    • 9
    • 9
    • 8
    • 5
    • 3
    • 2
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunofluorescence (IF)
    Sequence
    MRPMRIFVND DRHVMAKHSS VYPTQEELEA VQNMVSHTER ALKAVSDWID EQEKGSSEQA ESDNMDVPPE DDSKEGAGEQ KTEHMTRTLR GVMRVGLVAK GLLLKGDLDL ELVLLCKEKP TTALLDKVAD NLAIQLAAVT EDKYEILQSV DDAAIVIKNT KEPPLSLTIH LTSPVVREEM EKVLAGETLS VNDPPDVLDR QKCLAALASL RHAKWFQARA NGLKSCVIVI RVLRDLCTRV PTWGPLRGWP LELLCEKSIG TANRPMGAGE
    Cross-Reactivity
    Human, Mouse, Rat
    Characteristics
    Polyclonal Antibodies
    Immunogen
    Recombinant fusion protein containing a sequence corresponding to amino acids 1-270 of human ILF3 (NP_036350.2).
    Isotype
    IgG
    Top Product
    Discover our top product ILF3 Primary Antibody
  • Application Notes
    WB,1:500 - 1:2000,IHC,1:50 - 1:200,IF,1:50 - 1:200,IP,1:50 - 1:200
    Restrictions
    For Research Use only
  • Buffer
    PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    -20 °C
    Storage Comment
    Store at -20°C. Avoid freeze / thaw cycles.
  • Target
    Interleukin enhancer-binding factor 3 (ILF3)
    Alternative Name
    ILF3 (ILF3 Products)
    Synonyms
    CBTF antibody, DRBF antibody, DRBP76 antibody, MMP4 antibody, MPHOSPH4 antibody, MPP4 antibody, NF-AT-90 antibody, NF110 antibody, NF110b antibody, NF90 antibody, NF90a antibody, NF90b antibody, NFAR antibody, NFAR-1 antibody, NFAR2 antibody, TCP110 antibody, TCP80 antibody, MBII-26 antibody, ilf3 antibody, wu:fb37d07 antibody, wu:fb94b02 antibody, zgc:77030 antibody, 4F.1 antibody, cbtf122 antibody, ilf3-A antibody, ubp3 antibody, ubp4 antibody, xilf3 antibody, interleukin enhancer binding factor 3 antibody, interleukin enhancer binding factor 3b antibody, interleukin enhancer binding factor 3 S homeolog antibody, ILF3 antibody, Ilf3 antibody, ilf3b antibody, ilf3.S antibody
    Background
    This gene encodes a double-stranded RNA (dsRNA) binding protein that complexes with other proteins, dsRNAs, small noncoding RNAs, and mRNAs to regulate gene expression and stabilize mRNAs. This protein (NF90, ILF3) forms a heterodimer with a 45 kDa transcription factor (NF45, ILF2) required for T-cell expression of interleukin 2. This complex has been shown to affect the redistribution of nuclear mRNA to the cytoplasm. Knockdown of NF45 or NF90 protein retards cell growth, possibly by inhibition of mRNA stabilization. In contrast, an isoform (NF110) of this gene that is predominantly restricted to the nucleus has only minor effects on cell growth when its levels are reduced. Alternative splicing results in multiple transcript variants encoding distinct isoforms.,ILF3,CBTF,DRBF,DRBP76,MMP4,MPHOSPH4,MPP4,NF-AT-90,NF110,NF110b,NF90,NF90a,NF90b,NFAR,NFAR-1,NFAR2,TCP110,TCP80,Epigenetics & Nuclear Signaling,Transcription Factors,RNA Binding,Signal Transduction,ILF3
    Molecular Weight
    74 kDa/75 kDa/76 kDa/82 kDa/95 kDa
    Gene ID
    3609
    UniProt
    Q12906
    Pathways
    M Phase
You are here:
Support